To include your compound in the COVID-19 Resource Center, submit it here.

Neuralstem's NSI-189 misses in Phase II for MDD

Neuralstem Inc. (NASDAQ:CUR) reported top-line data from a Phase II trial in 220 patients with major depressive disorder (MDD) showing that

Read the full 215 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE